Citations

Clear

5 citation(s) found for "Simon, Nicholas".

Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors
Zarif, Talal El , Pond, Gregory R. , Zhuang, Tony , Master, Viraj A. , Nazha, Bassel , Niglio, Scot A. , Simon, Nicholas I. , Hahn, Andrew W. , Pettaway, Curtis A. , Tu, Shi‐Ming, Abdel‐Wahab, Noha , Velev, Maud , Flippot, Ronan , Maruzzo, Marco , Yang, Yuanquan , Rodriguez, Pablo Alvarez, Castellano, Daniel , Velasco, Guillermo de , Roviello, Giandomenico , Antonuzzo, Lorenzo , McKay, Rana R. , Hui, Gavin , Drakaki, Alexandra , Glover, Michael , Khaki, Ali Raza , El‐Am, Edward , Patel, Vaibhav G. , Piedra, A. , Gernone, Angela , Davis, Nancy B. , Matthews, Harrison, Giudice, Giulia Claire , Farolfi, Alberto , Milowsky, Matthew I. , Appleman, Leonard J. , Freeman, Dory , Sonpavde, Guru , El Zarif, Talal , Nazha, Bassel , Hahn, Andrew W , Antonuzzo, Lorenzo , Khaki, Ali Raza , El-Am, Edward , Appleman, Leonard , Choueiri, Toni K , Spiess, Philippe E , Necchi, Andrea , Sonpavde, Guru , Pond, Gregory Russell , Nassar, Amin H. , Tu, Shi‐Ming , Buti, Sebastiano , Mittra, Arjun , Gheeya, Jinesh , Vincenzi, Bruno , Cortellini, Alessio , Drakaki, Alexandra , Adra, Nabil , Mouhieddine, Tarek H. , Harrison, Michael R. , Kanesvaran, Ravindran , Barata, Pedro C. , Lee, Jae‐Lyun , Stahlfeld, Charlotte N. , Kim, Joseph W. , Choueiri, Toni K. , Spiess, Philippe E. , Necchi, Andrea , Apolo, Andrea B

Mayo Clinic

JNCI: Journal of the National Cancer Institute | August 11, 2023 | Volume: 115 | Issue: 12 | Pages: 1605-1615

10.1093/jnci/djad155 | PMID 37563779 Get It

Abstract Background Treatment options for penile squamous cell carcinoma are limited. We sought to investigate clinical outcomes and safety profiles of patients with penile squamous cell carcinoma receiving immune checkpoint inhibitors. Methods This retrospective study included patients with locally advanced or metastatic penile squamous cell carcinoma receiving immune checkpoint inhibitors between 2015 and 2022 across 24 centers in the United States, Europe, and Asia. Overall survival and progression-free survival were estimated using the Kaplan-Meier method. Objective response rates were determined per Response Evaluation Criteria in Solid Tumours 1.1 criteria. Treatment-related adverse events were graded per the Common Terminology Criteria for Adverse Events, version 5.0. Two-sided statistical tests were used for comparisons. Results Among 92 patients, 8 (8.7%) were Asian, 6 (6.5%) were Black, and 24 (29%) were Hispanic and/or Latinx. Median (interquartile range) age was 62 (53-70) years. In all, 83 (90%) had metastatic penile squamous cell carcinoma, and 74 (80%) had received at least second-line treatment. Most patients received pembrolizumab monotherapy (n = 26 [28%]), combination nivolumab-ipilimumab with or without multitargeted tyrosine kinase inhibitors (n = 23 [25%]), or nivolumab (n = 16 [17%]) or cemiplimab (n = 15 [16%]) monotherapies. Median overall and progression-free survival were 9.8 months (95% confidence interval = 7.7 to 12.8 months) and 3.2 months (95% confidence interval = 2.5 to 4.2 months), respectively. The objective response rate was 13% (n = 11/85) in the overall cohort and 35% (n = 7/20) in patients with lymph node–only metastases. Visceral metastases, Eastern Cooperative Oncology Group (ECOG) performance status of 1 or higher, and a higher neutrophil/lymphocyte ratio were associated with worse overall survival. Treatment-related adverse events occurred in 27 (29%) patients, and 9.8% (n = 9) of the events were grade 3 or higher. Conclusions Immune checkpoint inhibitors are active in a subset of patients with penile squamous cell carcinoma. Future translational studies are warranted to identify patients more likely to derive clinical benefit from immune checkpoint inhibitors.
Evolving Role of Adjuvant Systemic Therapy for Kidney and Urothelial Cancers
Niglio, Scot A. , Simon, Nicholas I. , Maskens, Deborah , Weinstock, Chana , Apolo, Andrea B , Msaouel, Pavlos , Chandran, Elias B. A. , Perez, Gabriela, Ballman, Karla V.

Mayo Clinic

American Society of Clinical Oncology Educational Book | May 24, 2022 | Volume: No volume available | Issue: 42 | Pages: 311-326

10.1200/edbk_350829 | PMID 35609225 Get It

The role of adjuvant therapy in renal cell carcinoma and urothelial carcinoma is rapidly evolving. To date, the U.S. Food and Drug Administration has approved sunitinib and pembrolizumab in the adjuvant setting for renal cell carcinoma and nivolumab for urothelial carcinoma based on disease-free survival benefit. The U.S. Food and Drug Administration held a joint workshop with the National Cancer Institute and the Society of Urologic Oncology in 2017 to harmonize design elements, including eligibility and radiologic assessments across adjuvant trials in renal cell carcinoma and urothelial carcinoma. Considerations from the discussion at these workshops led the U.S. Food and Drug Administration to draft guidances to help inform subsequent adjuvant trial design for renal cell carcinoma and urothelial carcinoma. Patient-centered decision-making is crucial when determining therapeutic choices in the adjuvant setting; utility functions can be used to help quantify each patient’s goals, values, and risk/benefit trade-offs to ensure that the decision regarding adjuvant therapy is informed by their preferences and the evolving outcomes data.
Artificial Intelligence and Machine Learning in Arrhythmias and Cardiac Electrophysiology
Feeny, Albert , Chung, Mina K. , Attia, Zachi I. , Čikeš, Maja , Firouznia, Marjan , Friedman, Paul A. , Kalscheur, Matthew M. , Narayan, Sanjiv M. , Piccini, Jonathan P. , Tarakji, Khaldoun G. , Thomas, Suma A., Turakhia, Mintu P. , Wang, Paul J. , Attia, Zachi I , Kalscheur, Matthew M , Turakhia, Mintu P , Narayan, Sanjiv M , Madabhushi, Anant , Kapa, Suraj , Noseworthy, Peter A. , Passman, Rod , Pérez, Marco , Peters, Nicholas Simon , Trayanova, Natalia A.

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | July 6, 2020 | Volume: 13 | Issue: 8 | Pages: No page available

10.1161/circep.119.007952 | PMID 32628863 Get It

Artificial intelligence (AI) and machine learning (ML) in medicine are currently areas of intense exploration, showing potential to automate human tasks and even perform tasks beyond human capabilities. Literacy and understanding of AI/ML methods are becoming increasingly important to researchers and clinicians. The first objective of this review is to provide the novice reader with literacy of AI/ML methods and provide a foundation for how one might conduct an ML study. We provide a technical overview of some of the most commonly used terms, techniques, and challenges in AI/ML studies, with reference to recent studies in cardiac electrophysiology to illustrate key points. The second objective of this review is to use examples from recent literature to discuss how AI and ML are changing clinical practice and research in cardiac electrophysiology, with emphasis on disease detection and diagnosis, prediction of patient outcomes, and novel characterization of disease. The final objective is to highlight important considerations and challenges for appropriate validation, adoption, and deployment of AI technologies into clinical practice.
2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation
Calkins, Hugh , Hindricks, Gerhard , Cappato, Riccardo , Kim, Young‐Hoon , Aguinaga, Luis, Akar, Joseph G. , Badhwar, Vinay , Camm, A. John , Chen, Peng‐Sheng , Chen, Shih‐Ann , Chung, Mina K. , Nielsen, Jens Cosedis , Curtis, Anne B. , Davies, D. Wyn, Groot, Natasja M.S. de , Duytschaever, Mattias , Edgerton, James R. , Ellenbogen, Kenneth A. , Ernst, Sabine , Fenelon, Guilherme , Gerstenfeld, Edward P. , Haines, David E. , Haïssaguerre, Michel , Jackman, Warren M. , Jalife, José , Kalman, Jonathan M. , Kautzner, Josef , Kottkamp, Hans , Kuck, Karl Heinz, Kumagai, Koichiro , Lee, Richard, Lewalter, Thorsten , Lindsay, Bruce D., Mansour, Moussa , Michaud, Gregory F., Nakagawa, Hiroshi , Natale, Andrea , Okumura, Ken , Packer, Douglas L. , Reynolds, Matthew R. , Sanders, Prashanthan , Scanavacca, Maurício , Schilling, Richard J. , Tondo, Claudio , Tsao, Hsuan-Ming, Verma, Atul , Wilber, David J. , Reviewers:, Document, Paola, Ângelo Amato Vincenzo de , Kistler, Peter M. , Pisani, Cristiano , Raviele, Antonio , Satomi, Kazuhiro , Stiles, Martin K. , Willems, Stephan , Haı̈ssaguerre, Michel , Packer, Douglas, Verma, Atul , Natale, Andrea , Sanders, Prashanthan , Nielsen, Jens C , de Groot, Natasja M S , Saad, Eduardo , Brugada, Josép , Day, John , d'Avila, Andre , Biase, Luigi Di , Ellinor, Patrick T. , Haissaguerre, Michel , Helm, Robert H. , Hylek, Elaine M. , Macle, Laurent , Marchlinski, Francis E. , Michaud, Gregory F. , Nattel, Stanley , Pokushalov, Evgeny A. , Tsao, Hsuan-Ming, Yamane, Teiichi , Reviewers:, Document, Blomström‐Lundqvist, Carina , Lip, Gregory Y H , Peters, Nicholas Simon , Scanavacca, Maurício , Tondo, Claudio , Ernst, Sabine , Ellenbogen, Kenneth A

Mayo Clinic

EP Europace | January 17, 2018 | Volume: 20 | Issue: 1 | Pages: e1-e160

10.1093/europace/eux274 | PMID 29016840 Get It